While CLU inhibition potentiates the activity of many anti‐cancer therapies in preclinical models (Miyake et al, 2005a,b; Zoubeidi et al, 2010; Chun, 2014), the CLU inhibitor custirsen (OGX‐011) failed to prolong survival when combined with docetaxel in CRPC (Chi et al, 2015). The gene discussed is CLU; the disease is cancer.